References
- Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. : Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay : clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55 : 5276-5282, 1995
- Bogdahn U : Chemosensitivity of malignant human brain tumors. Preliminary results. J Neurooncol 1 : 149-166, 1983
- Boiardi A, Eoli M, Salmaggi A, Pollo B, Milanesi I, Broggi G, et al. : Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. J Neurooncol 49 : 71-75, 2000 https://doi.org/10.1023/A:1006489919811
- Choi IS, Lee SH, Kim TY, Bang JS, Paek SH, Kim S, et al. : Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 60 : 171-176, 2002 https://doi.org/10.1023/A:1020605617452
- Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP : Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 : 2585-2597, 1993 https://doi.org/10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S
- Furukawa T, Kubota T, Hoffman RM : Clinical applications of the histoculture drug response assay. Clin Cancer Res 1 : 305-311, 1995
- Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, et al. : High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51 : 489-498, 1992 https://doi.org/10.1002/ijc.2910510325
- Gilbert M, O'Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, et al. : A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme : an Eastern Cooperative Oncology Group study (E2393). J Neurooncol 47 : 145-152, 2000 https://doi.org/10.1023/A:1006402123397
- Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al. : Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme : Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21 : 1485-1491, 2003 https://doi.org/10.1200/JCO.2003.10.035
- Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, et al. : Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15 : 2596-2603, 1997 https://doi.org/10.1200/JCO.1997.15.7.2596
- Guo HY, Colangelo D, Li L, Connors KM, Kubota T, Hoffman RM : In vitro histoculture of human tumors with fluorescent dye end-points measured by confocal microscopy : high correlation of in vitro and in vivo chemosensitivity. Anticancer Res 12 : 1055-1061, 1992
- Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH : ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas : phase II study. J Neurooncol 75 : 173-180, 2005 https://doi.org/10.1007/s11060-005-1858-8
- Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, et al. : Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43 : 749-756, 2007 https://doi.org/10.1016/j.oraloncology.2006.09.003
- Haselsberger K, Peterson DC, Thomas DG, Darling JL : Assay of anticancer drugs in tissue culture : comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. Anticancer Drugs 7 : 331-338, 1996 https://doi.org/10.1097/00001813-199605000-00014
- Hirano Y, Ushiyama T, Suzuki K, Fujita K : Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers : wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 27 : 483-488, 1999 https://doi.org/10.1007/s002400050139
- Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT : High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54 : 455-460, 1981 https://doi.org/10.3171/jns.1981.54.4.0455
- Iwadate Y, Fujimoto S, Namba H, Yamaura A : Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br J Cancer 89 : 1896-1900, 2003 https://doi.org/10.1038/sj.bjc.6601376
- Kanasugi M, Aoki D, Suzuki N, Susumu N, Nakata S, Horiuchi M, et al. : Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. Int J Gynecol Cancer 16 : 409-415, 2006 https://doi.org/10.1111/j.1525-1438.2006.00409.x
- Kim IK, Yoo H, Shin SH, Youn SM, Rhee CH, Lee SH, et al. : Histoculture drug response assay for brain tumors : a preliminary study for evaluability and compatibility. J Korean Brain Tumor Soc 9 : 67-73, 2010
- Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, et al. : Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24 : 209-218, 2009 https://doi.org/10.1007/s00384-008-0590-1
- Kochii M, Kitamura I, Goto T, Nishi T, Takeshima H, Saito Y, et al. : Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol 49 : 63-70, 2000 https://doi.org/10.1023/A:1006457502972
- Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. : In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 11 : 449-453, 2006 https://doi.org/10.1007/s10147-006-0618-x
- Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. : Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1 : 1537-1543, 1995
- Lassen U, Kristjansen PE, Wagner A, Kosteljanetz M, Poulsen HS : Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol 43 : 161-166, 1999 https://doi.org/10.1023/A:1006254716877
- Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, et al. : Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64 : 237-244, 1980
- Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase III studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990 https://doi.org/10.1200/JCO.1990.8.7.1277
- Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, et al. : In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 21 : 4147-4151, 2001
- Mosmann T : Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays. J Immunol Methods 65 : 55-63, 1983 https://doi.org/10.1016/0022-1759(83)90303-4
- Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, et al. : Chemosensitivity testing of ovarian cancer using the histoculture drug response assay : sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15 : 445-452, 2005 https://doi.org/10.1111/j.1525-1438.2005.15307.x
- Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, et al. : Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20 : 2049-2054, 2000
- Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, et al. : In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer 44 : 142-146, 2007 https://doi.org/10.4103/0019-509X.39376
- Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. : High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma : European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 : 4483-4488, 2003 https://doi.org/10.1200/JCO.2003.03.108
- Qin D, Ou G, Mo H, Song Y, Kang G, Hu Y, et al. : Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier : clinical results. Int J Radiat Oncol Biol Phys 51 : 959-962, 2001 https://doi.org/10.1016/S0360-3016(01)01735-7
- Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, et al. : Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide : a phase II study. Eur J Cancer 32A : 2229-2235, 1996
- Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR : American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22 : 3631-3638, 2004 https://doi.org/10.1200/JCO.2004.05.065
- Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, et al. : Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24 : 437-442, 2002 https://doi.org/10.1002/hed.10066
- Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W : The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines : analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 22 : 137-140, 1988
- Stewart LA : Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-1018, 2002 https://doi.org/10.1016/S0140-6736(02)08091-1
- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005 https://doi.org/10.1056/NEJMoa043330
- Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A : Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 32 : 477-481, 2002 https://doi.org/10.1007/s005950200080
- Vescio RA, Connors KM, Kubota T, Hoffman RM : Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci U S A 88 : 5163-5166, 1991 https://doi.org/10.1073/pnas.88.12.5163
- Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM : In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A 84 : 5029-5033, 1987 https://doi.org/10.1073/pnas.84.14.5029
- Weaver JR, Wientjes MG, Au JL : Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol 44 : 335-342, 1999 https://doi.org/10.1007/s002800050986
- Wen PY, Kesari S : Malignant gliomas in adults. N Engl J Med 359 : 492-507, 2008 https://doi.org/10.1056/NEJMra0708126
- Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010 https://doi.org/10.1200/JCO.2009.26.3541
- Yamauchi M, Satta T, Ito A, Kondo T, Takagi H : A feasibility study of the SDI test for the evaluation of gastrointestinal cancer sensitivity to anticancer drugs. J Surg Oncol 47 : 253-260, 1991 https://doi.org/10.1002/jso.2930470410
- Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Hata K, et al. : Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 133 : 303-308, 2007 https://doi.org/10.1016/j.jtcvs.2006.06.030
- Yung WK : In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12 : 197-203, 1989 https://doi.org/10.1007/BF01743984
- Yung WK, Janus TJ, Maor M, Feun LG : Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol 12 : 131-135, 1992
Cited by
- Long Noncoding RNA MRUL Promotes ABCB1 Expression in Multidrug-Resistant Gastric Cancer Cell Sublines vol.34, pp.17, 2011, https://doi.org/10.1128/mcb.01580-13
- Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme vol.119, pp.2, 2011, https://doi.org/10.1007/s11060-014-1504-4
- Multidrug-Resistance Related Long Non-Coding RNA Expression Profile Analysis of Gastric Cancer vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0135461
- Validation of a preclinical model for assessment of drug efficacy in melanoma vol.7, pp.11, 2011, https://doi.org/10.18632/oncotarget.7541
- Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells vol.14, pp.None, 2011, https://doi.org/10.1186/s12967-016-0803-2
- Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines vol.17, pp.None, 2011, https://doi.org/10.1186/s12935-017-0441-7